Cargando…
A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron(®) (Peginterferon alfa-2b) and Actimmune(®) (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer
BACKGROUND: Ovarian cancer has no definitive second line therapeutic options, and largely recurs in the peritoneal cavity. Locoregional immune therapy using both interferons and monocytes can be used as a novel approach. Interferons have both cytostatic and cytotoxic properties, while monocytes stim...
Autores principales: | Green, Daniel S., Nunes, Ana T., David-Ocampo, Virginia, Ekwede, Irene B., Houston, Nicole D., Highfill, Steven L., Khuu, Hanh, Stroncek, David F., Steinberg, Seth M., Zoon, Kathryn C., Annunziata, Christina M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048715/ https://www.ncbi.nlm.nih.gov/pubmed/30012146 http://dx.doi.org/10.1186/s12967-018-1569-5 |
Ejemplares similares
-
Production of a cellular product consisting of monocytes stimulated with Sylatron(®) (Peginterferon alfa-2b) and Actimmune(®) (Interferon gamma-1b) for human use
por: Green, Daniel S., et al.
Publicado: (2019) -
Cost-Efficacy Analysis of Peginterferon alfa-2b plus Ribavirin Compared With Peginterferon alfa-2a plus Ribavirin for the Treatment of Chronic Hepatitis C
por: Malone, Daniel C., et al.
Publicado: (2005) -
Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil
por: Barros, Fabio MR, et al.
Publicado: (2013) -
A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma
por: Brohl, Andrew S., et al.
Publicado: (2016) -
Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B
por: Marcellin, Patrick, et al.
Publicado: (2020)